- Ongoing, recruitingTherapeutic use (Phase IV)
I4V-MC-JAJA (RA-BRIDGE): A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis
This study looks at how safe and effective a medicine called baricitinib is for people with rheumatoid arthritis, compared to other common treatments. It will see how long it takes for a blood clot to happen. This is a long-term study that will last over five years.
For: Rheumatoid ArthritisHungary · Slovakia · Lithuania - Active not recruitingPHASE3
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
This study compares two treatments, abatacept and adalimumab, for adults with early, severe rheumatoid arthritis who haven't responded well to methotrexate. It aims to see which treatment is better at reducing arthritis symptoms and improving quality of life.
For: Rheumatoid ArthritisUnited States · Argentina · Australia - Active not recruitingPHASE3
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
This study looks at two medicines, upadacitinib and adalimumab, for adults with moderate to severe Rheumatoid Arthritis (RA). It checks how safe and effective they are. Upadacitinib is a pill, and adalimumab is an injection. This helps us understand which treatment works best.
For: Rheumatoid ArthritisUnited States · Argentina · Belgium - Active not recruitingPHASE3
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
This study is testing a new medicine called ixekizumab for children aged 2-17 with two types of juvenile arthritis: enthesitis-related arthritis (including a form of arthritis affecting the spine) and juvenile psoriatic arthritis. We want to see if it's safe and helps improve their condition, comparing it to another common medicine, adalimumab.
For: Juvenile Psoriatic Arthritis · Enthesitis Related ArthritisArgentina · Belgium · Czechia - Active not recruitingPHASE3
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
This study is looking at a new medicine called baricitinib for children and young people aged 2 to 17 who have a specific eye condition called uveitis. We want to see if it's safe and helps reduce eye inflammation, especially for those who haven't responded well to other treatments.
For: UveitisFrance · Germany · Italy - Active not recruitingPHASE2
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
This study looks at a new medicine called lutikizumab for adults with moderate to severe ulcerative colitis. It aims to see if it's safe and how well it works compared to a common treatment called adalimumab.
For: Ulcerative ColitisUnited States · Australia · Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Pilot study RCT anti-NGF Adalimumab versus placebo in fasciotomy Dupuytren contracture
This study is testing a new medicine called Adalimumab for Dupuytren's disease, a hand condition. Researchers want to see if this medicine can help straighten fingers better than a dummy treatment after surgery. The main goal is to improve finger movement by at least 10 degrees.
For: Dupuytren DiseaseBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
CO-THEIA (COMBINATION THERAPY WITH METHOTREXATE AND ADALIMUMAB FOR UVEITIS): EFFICACY, SAFETY AND COST-EFFECTIVENESS OF METHOTREXATE, ADALIMUMAB, OR THEIR COMBINATION IN NON INFECTIOUS NON ANTERIOR UVEITIS: A MULTICENTER, RANDOMIZED, PARALLEL 3 ARMS, ACTIVE-CONTROLLED, PHASE 3 OPEN LABEL WITH BLINDED OUTCOME ASSESSMENT STUDY.
This study looks at new ways to treat a serious eye condition called non-infectious uveitis. It compares a combination of two medicines, methotrexate and adalimumab, to using each medicine alone, to see which works best and is safest for patients.
For: Non-infection uveitisSpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Multicenter Induction Study with an Active Treatment Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients with Moderate to Severe Ulcerative Colitis
This study is testing a new drug, called Vixarelimab, for adults with moderate to severe ulcerative colitis. It aims to see how well it works to reduce symptoms and improve the gut, as well as checking its safety and how the body handles it.
For: Ulcerative Colitis (UC)Belgium · Germany · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease
This study looks at new ways to treat serious, ongoing inflammatory diseases that haven't responded to other treatments. Researchers are testing different existing medicines to see which ones work best to reduce inflammation and improve symptoms in patients with complex conditions.
For: Patients displaying a non-classified · severe and resistant inflammatory diseaseFrance - Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
For: Rheumatoid ArthritisUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
This study looks at a new medicine called risankizumab for children aged 5-17 with a type of arthritis called juvenile psoriatic arthritis (jPsA). It aims to see how safe and effective it is compared to an existing medicine, adalimumab. Participants will receive injections.
For: Juvenile Psoriatic ArthritisUnited States · Australia · Canada - AuthorisedTherapeutic exploratory (Phase II)
BOOSTERS - BiOlogics in FOlliculitis decalvanS : an adaptaTivE tRial reSearch
This study looks at new treatments for folliculitis decalvans, a skin condition causing hair loss and scalp sores. Researchers are testing different medicines to see if they can reduce the severity of the condition and improve how people feel, aiming for clearer skin and less discomfort.
For: Folliculitis decalvansFrance - AuthorisedTherapeutic exploratory (Phase II)
STARS - Prospective, bayesian, randomized, controlled, open-label, parallel-group, phase II interventional study evaluating efficacy and safety of secukinumab versus standard of care in active severe Takayasu patients
This study, called STARS, is looking at a new medicine for Takayasu arteritis, a condition that makes blood vessels inflamed. Researchers want to see if this medicine, called secukinumab (Cosentyx), works better and is safer than usual treatments for severe forms of the disease.
For: TAkayasu ARteritiSFrance